The STELLAR trial: A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma

These data support the main findings described in 'The STELLAR trial: A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.

The data contains the results from the STELLAR trial, registered on ClinicalTrials.gov (NCT03025893). In total 55 patients were randomized 1:1 between treatment with high-dose intermittent sunitinib (either 300mg Q1W or 700mg Q2W) and lomustine. The trial was performed in three centers in the Netherlands (AmsterdamUMC, UMCG and Radboudumc).

Identifier
DOI https://doi.org/10.17026/dans-x38-pz3s
PID https://nbn-resolving.org/urn:nbn:nl:ui:13-n4-zrxh
Metadata Access https://easy.dans.knaw.nl/oai?verb=GetRecord&metadataPrefix=oai_datacite&identifier=oai:easy.dans.knaw.nl:easy-dataset:322956
Provenance
Creator Janssen, J.B.E. ORCID logo
Publisher Data Archiving and Networked Services (DANS)
Contributor Verheul, H.M.W.; Linde, M.E. Van; Radboudumc; AmsterdamUMC
Publication Year 2024
Rights info:eu-repo/semantics/restrictedAccess; License: http://dans.knaw.nl/en/about/organisation-and-policy/legal-information/DANSLicence.pdf; http://dans.knaw.nl/en/about/organisation-and-policy/legal-information/DANSLicence.pdf
OpenAccess false
Representation
Language English
Resource Type Dataset
Format .ods
Discipline Other